CX-5461 is currently tested in clinical trials for advanced hematological malignancies (Australian New Zealand Clinical Trials Registry 12613001061729) and solid tumors (ClinicalTrials.gov Identifier NCT02719977), and its use could be extended to clinical trials of MYC-driven solid tumors, including breast, ovarian and prostate cancer [19, 24, 32]. The gene discussed is MYC; the disease is hematologic disorder.